Piramal acquires florbetaben rights from Bayer
Sunday 15 April 2012
On 15 April, Piramal Healthcare announced that it has signed an agreement to acquire worldwide rights to the molecular imaging research and development portfolio of Bayer. This includes the rights to florbetaben, a PET tracer for the detection of beta-amyloid plaque deposition in the living brain.
Florbetaben (BAY 94-9172) is in the final stages of a Phase III clinical trial and the first results are expected soon.